Economic Analysis of the EPRIDE

尿失禁(Ul)是女性中常见的问题，会导致痛苦和日常生活受限。 功能正常。Ul的成本是巨大的，在美国每年占160亿至320亿美元，超过 所有乳腺癌和妇科癌症的年度直接成本加起来。UL在很大程度上影响了 它与严重受损的健康状况有关，类似于阿尔茨海默病和中风。 较高的体重会增加下尿路感染的风险，初步数据表明体重减轻会改善下尿路感染。至 进一步评估UL治疗的减肥效果，NIDDK赞助该计划以 通过饮食和运动减少尿失禁(PROID)，一项对330名患有尿失禁的肥胖女性随机分为A组的研究 减肥计划或控制条件(关于饮食和锻炼的信息会议和讲义)。 虽然减肥计划成本高昂，但它有可能改善UL，降低相关成本 UL和肥胖症，提高生活质量。这项拟议研究的目的是E-Pride(经济 Pride的分析)，是比较Pride减肥和控制的成本和收益 评估失禁减肥成本效用的干预措施。高经济性和高质量的 大小便失禁和肥胖的生命代价，以及随着减肥而改善的可能性很高，这使这一点成为 利用成本效用分析探索的重要领域。由于公用事业抓住了所有潜在的与健康相关的好处， 包括改进的UL和减轻的重量，成本效用分析是检验以下假设的理想方法 减肥的每质量调整寿命年(QALY)成本将与目前接受的成本相当 医疗干预。进行这种经济分析的必要步骤是：1)确定成本 与减肥和对照组相关；2)评估与健康相关的生活质量(公用事业) 与治疗和结果相关；以及3)估计减肥计划的成本效用 对控制条件的影响。为了评估UL变化的具体贡献，二次分析将 探索费用、与健康相关的生活质量和QALY的变化与UL和 重量。 E-Pride汇集了一群在经济、成本-方面有专长的高级调查人员 有效性、尿路感染和肥胖治疗。E-Pride的辅助研究使我们能够有效地评估 一种治疗大小便失禁的新治疗方法--减重--的成本效益。

Urinary incontinence (Ul) is a common problem among women that causes distress and limits daily functioning. The costs of Ul are substantial, accounting for $16 to $32 billion per year in the U.S., more than the annual direct costs for all breast and gynecological cancers combined. Ul substantially affects quality of life and is associated with severely impaired health status similar to Alzheimer's disease and stroke. Higher weight increases the risk of Ul and initial data suggest that weight reduction improves Ul. To further evaluate the efficacy of weight loss for Ul treatment, the NIDDK is sponsoring the Program to Reduce Incontinence by Diet and Exercise (PRIDE), a study of 330 obese women with Ul randomized to a weight reduction program or control condition (informational sessions & handouts on diet and exercise). While a weight loss program is costly, it has the potential to improve Ul, decrease costs associated with both Ul and obesity and improve quality of life. The aim of this proposed study, E-PRIDE (Economic analysis of the PRIDE), is to compare the costs and benefits of the PRIDE weight loss and control interventions to estimate the cost-utility of weight loss for incontinence. The high economic and quality of life costs of incontinence and obesity and the high probability of improvement with weight loss make this an important area to explore with cost-utility analysis. Since utilities capture all potential health-related benefits, including improved Ul and reduced weight, cost-utility analysis is an ideal method to test the hypothesis that weight loss will have a cost per quality adjusted life year (QALY) that is comparable with currently accepted medical interventions. The steps necessary to perform this economic analysis are to 1) determine costs associated with the weight loss and control groups; 2) assess the health-related quality of life (utilities) associated with treatments and outcomes; and 3) estimate the cost-utility of the weight reduction program vs. the control condition. To evaluate the specific contributions of changes in Ul, secondary analyses will explore the association of changes in costs, health-related quality of life and QALY's with changes in Ul and weight. E-PRIDE brings together a group of senior investigators with expertise in economics, cost- effectiveness, Ul and obesity treatment. The E- PRIDE ancillary study allows us to efficiently evaluate the cost-utility of a novel treatment approach - weight reduction -- for incontinence.